These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35780065)

  • 1. Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma.
    Heran M; Renaud F; Louvet C; Piessen G; Voron T; Lefèvre M; Dubreuil O; André T; Svrcek M; Cohen R
    Dig Liver Dis; 2023 Feb; 55(2):276-282. PubMed ID: 35780065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
    Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
    Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
    J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
    Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
    Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma.
    Evaristo G; Katz A; Ramírez-GarcíaLuna JL; Issac MSM; Sangwan V; Thai DV; Bertos N; Guiot MC; Camilleri-Broët S; Marcus V; Mueller C; Cools-Lartigue J; Fiset PO; Ferri LE
    Can J Surg; 2023; 66(1):E79-E87. PubMed ID: 36792128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
    Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
    J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer.
    Hong EK; Chalabi M; Landolfi F; Castagnoli F; Park SJ; Sikorska K; Aalbers A; van den Berg J; van Leerdam M; Lee JM; Beets-Tan R
    Eur J Cancer; 2022 Oct; 174():165-175. PubMed ID: 36029713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.
    Derieux S; Svrcek M; Manela S; Lagorce-Pages C; Berger A; André T; Taieb J; Paye F; Voron T
    Dig Liver Dis; 2020 Jan; 52(1):107-114. PubMed ID: 31427088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.
    Oh CR; Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Kang YK
    Gastric Cancer; 2024 Jul; 27(4):811-818. PubMed ID: 38555561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the reliability of MSI status and dMMR proteins deficiency screening on endoscopic biopsy material in esophagus and gastric adenocarcinoma.
    Asesio N; Mhamdi Aloui N; Bonnereau J; Lehmann-Che J; Bouhidel F; Kaci R; Corte H; Svrcek M; Minh MLT; Gornet JM; Cattan P; Allez M; Bertheau P; Aparicio T
    Dig Liver Dis; 2023 Aug; 55(8):1105-1113. PubMed ID: 37142454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection.
    Otsuka H; Murakami Y; Uemura K; Kondo N; Nakagawa N; Okada K; Seo S; Takahashi S
    J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):421-428. PubMed ID: 32219999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.